JP7494181B2 - 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 - Google Patents
置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 Download PDFInfo
- Publication number
- JP7494181B2 JP7494181B2 JP2021535539A JP2021535539A JP7494181B2 JP 7494181 B2 JP7494181 B2 JP 7494181B2 JP 2021535539 A JP2021535539 A JP 2021535539A JP 2021535539 A JP2021535539 A JP 2021535539A JP 7494181 B2 JP7494181 B2 JP 7494181B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- solvent
- substituted
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024083009A JP7724911B2 (ja) | 2018-12-19 | 2024-05-22 | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782298P | 2018-12-19 | 2018-12-19 | |
| US62/782,298 | 2018-12-19 | ||
| US201962879900P | 2019-07-29 | 2019-07-29 | |
| US62/879,900 | 2019-07-29 | ||
| PCT/US2019/067088 WO2020132014A1 (en) | 2018-12-19 | 2019-12-18 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024083009A Division JP7724911B2 (ja) | 2018-12-19 | 2024-05-22 | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514344A JP2022514344A (ja) | 2022-02-10 |
| JP2022514344A5 JP2022514344A5 (cg-RX-API-DMAC7.html) | 2023-01-20 |
| JP7494181B2 true JP7494181B2 (ja) | 2024-06-03 |
Family
ID=71098067
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535539A Active JP7494181B2 (ja) | 2018-12-19 | 2019-12-18 | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 |
| JP2024083009A Active JP7724911B2 (ja) | 2018-12-19 | 2024-05-22 | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024083009A Active JP7724911B2 (ja) | 2018-12-19 | 2024-05-22 | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 |
Country Status (29)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024109765A (ja) * | 2018-12-19 | 2024-08-14 | セルジーン コーポレイション | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019404022A1 (en) | 2018-12-19 | 2021-07-08 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| ES3047718T3 (en) | 2020-06-24 | 2025-12-04 | Celgene Corp | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| IL299256A (en) | 2020-06-24 | 2023-02-01 | Celgene Corp | Cerebellum binding compounds, their compounds and methods of treatment with them |
| WO2022019597A1 (ko) * | 2020-07-21 | 2022-01-27 | 주식회사 유빅스테라퓨틱스 | 안드로겐 수용체 분해용 화합물 및 이들의 의약 용도 |
| US20240025863A1 (en) | 2020-09-16 | 2024-01-25 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| TW202231269A (zh) | 2020-10-23 | 2022-08-16 | 美商拜歐斯瑞克斯公司 | Kras蛋白降解劑、其醫藥組合物及其治療應用 |
| US20240124418A1 (en) | 2020-12-14 | 2024-04-18 | Biotheryx, Inc. | Pde4 degraders, pharmaceutical compositions, and therapeutic applications |
| AU2022240688B2 (en) * | 2021-03-17 | 2024-07-11 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Furan fused ring-substituted glutarimide compound |
| EP4359404A4 (en) * | 2021-06-25 | 2025-06-04 | Celgene Corporation | Cereblon-binding compounds, compositions thereof and methods of treatment therewith |
| KR20240026939A (ko) * | 2021-06-25 | 2024-02-29 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| KR20240026946A (ko) * | 2021-06-25 | 2024-02-29 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| US20260174749A1 (en) * | 2022-11-09 | 2026-06-25 | Bristol-Myers Squibb Company | Combination therapy with substituted 3-((3-aminophenyl)amino)piperidine-2,6- dione compounds |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| WO2025235600A1 (en) * | 2024-05-07 | 2025-11-13 | Bristol-Myers Squibb Company | Processes for the preparation of substituted 3-((3-aminophenyl)amino) piperidine-2,6-dione compounds |
| WO2025235577A1 (en) * | 2024-05-09 | 2025-11-13 | Bristol-Myers Squibb Company | Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds |
| CN118993935B (zh) * | 2024-10-23 | 2025-02-14 | 江苏恒瑞医药股份有限公司 | 咪唑啉衍生物或其盐的制备方法 |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002501536A (ja) | 1997-05-30 | 2002-01-15 | セルジーン コーポレイション | 置換2−(2,6−ジオキソピペリジン−3−イル)−フタルイミド類及び1−オキソイソインドリン類ならびにTNFαレベルの減少方法 |
| US20080064876A1 (en) | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| JP2013532657A (ja) | 2010-07-22 | 2013-08-19 | アンドレイ・アレクサンドロビッチ・イワシェンコ | 環式n,n’−ジアリールチオ尿素及びn,n’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用 |
| JP2014510074A (ja) | 2011-03-10 | 2014-04-24 | スジョウ キンター ファーマシューティカルズ インコーポレイテッド | アンドロゲン受容体アンタゴニストおよびその使用 |
| JP2015526487A (ja) | 2012-09-04 | 2015-09-10 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドShanghai Hengrui Pharmaceutical Co., Ltd. | イミダゾリン誘導体、その製造法、およびそれらの医薬への適用 |
| WO2017123542A1 (en) | 2016-01-11 | 2017-07-20 | Janssen Pharmaceutica Nv | Substituted thiohydantoin derivatives as androgen receptor antagonists |
| JP2017522379A (ja) | 2014-07-08 | 2017-08-10 | アール−ファーム オーバーシーズ インク.R−Pharm Overseas Inc. | 置換2−チオキソ−イミダゾリジン−4−オン及びそのスピロ類似体、抗癌有効成分、医薬組成物、医薬製剤、並びに前立腺癌の治療法 |
| US20180008587A1 (en) | 2016-07-08 | 2018-01-11 | Jaressen Pharmaceutica NV | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| JP2018502925A (ja) | 2015-01-20 | 2018-02-01 | アルビナス インコーポレイテッド | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| JP2022514347A (ja) | 2018-12-19 | 2022-02-10 | セルジーン コーポレイション | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4302485A1 (de) | 1993-01-29 | 1994-08-04 | Merck Patent Gmbh | Piperazinderivate |
| FR2768729A1 (fr) | 1997-09-19 | 1999-03-26 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique et complexes catalytiques |
| FR2768728B1 (fr) | 1997-09-19 | 1999-12-03 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| KR20070106969A (ko) | 2004-09-09 | 2007-11-06 | 추가이 세이야쿠 가부시키가이샤 | 신규 이미다졸리딘 유도체 및 그 용도 |
| WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| WO2011008260A2 (en) | 2009-07-13 | 2011-01-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| US20140112922A1 (en) | 2011-03-28 | 2014-04-24 | Cornell University | Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| KR102226587B1 (ko) | 2013-01-31 | 2021-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드 |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| TWI739888B (zh) | 2016-10-07 | 2021-09-21 | 美商陶氏農業科學公司 | 農藥組合物及方法 |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| WO2018089736A1 (en) | 2016-11-10 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| AU2017363257B2 (en) | 2016-11-22 | 2021-08-19 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use |
| RU2747260C2 (ru) | 2016-12-19 | 2021-04-29 | Аббиско Тхерапеутицс Цо., Лтд. | Ингибитор рфрф4, способ его получения и его фармацевтическое применение |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN109422725A (zh) | 2017-09-04 | 2019-03-05 | 北京美倍他药物研究有限公司 | 前列腺癌治疗药物 |
| HUE064356T2 (hu) | 2017-11-28 | 2024-03-28 | Aarti Pharmalabs Ltd | Eljárás enzalutamid elõállítására új intermedier felhasználásával |
| CN111163638B (zh) | 2017-12-05 | 2023-07-25 | 美国陶氏益农公司 | 杀有害生物组合物和方法 |
| AU2019276514B2 (en) | 2018-05-30 | 2023-12-14 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof |
| CN109651256A (zh) | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式(viii)的恩杂鲁胺的制备方法 |
| BR112021011968A2 (pt) * | 2018-12-19 | 2021-09-08 | Celgene Corporation | Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos |
-
2019
- 2019-12-18 BR BR112021011968-0A patent/BR112021011968A2/pt unknown
- 2019-12-18 HR HRP20250095TT patent/HRP20250095T1/hr unknown
- 2019-12-18 AU AU2019403207A patent/AU2019403207B2/en active Active
- 2019-12-18 KR KR1020257032139A patent/KR20250144505A/ko active Pending
- 2019-12-18 PT PT199013830T patent/PT3897636T/pt unknown
- 2019-12-18 IL IL284223A patent/IL284223B2/en unknown
- 2019-12-18 HU HUE19901383A patent/HUE070506T2/hu unknown
- 2019-12-18 CA CA3124130A patent/CA3124130A1/en active Pending
- 2019-12-18 MY MYPI2021003454A patent/MY205718A/en unknown
- 2019-12-18 JP JP2021535539A patent/JP7494181B2/ja active Active
- 2019-12-18 ES ES19901383T patent/ES3009308T3/es active Active
- 2019-12-18 EP EP19901383.0A patent/EP3897636B1/en active Active
- 2019-12-18 KR KR1020217019479A patent/KR102866144B1/ko active Active
- 2019-12-18 DK DK19901383.0T patent/DK3897636T3/da active
- 2019-12-18 SG SG11202106507RA patent/SG11202106507RA/en unknown
- 2019-12-18 CN CN201980092358.2A patent/CN113453681B/zh active Active
- 2019-12-18 SM SM20250111T patent/SMT202500111T1/it unknown
- 2019-12-18 SI SI201930889T patent/SI3897636T1/sl unknown
- 2019-12-18 CN CN202411325996.3A patent/CN119219606A/zh active Pending
- 2019-12-18 TW TW108146514A patent/TWI820276B/zh active
- 2019-12-18 FI FIEP19901383.0T patent/FI3897636T3/fi active
- 2019-12-18 RS RS20250148A patent/RS66556B1/sr unknown
- 2019-12-18 MX MX2021007473A patent/MX2021007473A/es unknown
- 2019-12-18 EP EP24218737.5A patent/EP4494711A3/en active Pending
- 2019-12-18 LT LTEPPCT/US2019/067088T patent/LT3897636T/lt unknown
- 2019-12-18 PE PE2021000924A patent/PE20212247A1/es unknown
- 2019-12-18 PL PL19901383.0T patent/PL3897636T3/pl unknown
- 2019-12-18 US US16/719,171 patent/US11149007B2/en active Active
- 2019-12-18 WO PCT/US2019/067088 patent/WO2020132014A1/en not_active Ceased
-
2021
- 2021-06-18 CO CONC2021/0007973A patent/CO2021007973A2/es unknown
- 2021-06-18 ZA ZA2021/04200A patent/ZA202104200B/en unknown
- 2021-06-18 CL CL2021001665A patent/CL2021001665A1/es unknown
- 2021-08-16 US US17/403,742 patent/US11873283B2/en active Active
-
2023
- 2023-11-28 US US18/521,663 patent/US12404241B2/en active Active
-
2024
- 2024-05-22 JP JP2024083009A patent/JP7724911B2/ja active Active
-
2025
- 2025-07-28 US US19/283,024 patent/US20260193185A1/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002501536A (ja) | 1997-05-30 | 2002-01-15 | セルジーン コーポレイション | 置換2−(2,6−ジオキソピペリジン−3−イル)−フタルイミド類及び1−オキソイソインドリン類ならびにTNFαレベルの減少方法 |
| US20080064876A1 (en) | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| JP2013532657A (ja) | 2010-07-22 | 2013-08-19 | アンドレイ・アレクサンドロビッチ・イワシェンコ | 環式n,n’−ジアリールチオ尿素及びn,n’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用 |
| JP2014510074A (ja) | 2011-03-10 | 2014-04-24 | スジョウ キンター ファーマシューティカルズ インコーポレイテッド | アンドロゲン受容体アンタゴニストおよびその使用 |
| JP2015526487A (ja) | 2012-09-04 | 2015-09-10 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドShanghai Hengrui Pharmaceutical Co., Ltd. | イミダゾリン誘導体、その製造法、およびそれらの医薬への適用 |
| JP2017522379A (ja) | 2014-07-08 | 2017-08-10 | アール−ファーム オーバーシーズ インク.R−Pharm Overseas Inc. | 置換2−チオキソ−イミダゾリジン−4−オン及びそのスピロ類似体、抗癌有効成分、医薬組成物、医薬製剤、並びに前立腺癌の治療法 |
| JP2018502925A (ja) | 2015-01-20 | 2018-02-01 | アルビナス インコーポレイテッド | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| WO2017123542A1 (en) | 2016-01-11 | 2017-07-20 | Janssen Pharmaceutica Nv | Substituted thiohydantoin derivatives as androgen receptor antagonists |
| US20180008587A1 (en) | 2016-07-08 | 2018-01-11 | Jaressen Pharmaceutica NV | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| JP2022514347A (ja) | 2018-12-19 | 2022-02-10 | セルジーン コーポレイション | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療法 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024109765A (ja) * | 2018-12-19 | 2024-08-14 | セルジーン コーポレイション | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 |
| JP7724911B2 (ja) | 2018-12-19 | 2025-08-18 | セルジーン コーポレイション | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404241B2 (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
| JP7781792B2 (ja) | セレブロン結合化合物、その組成物及びそれによる治療方法 | |
| JP7492962B2 (ja) | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療法 | |
| JP7781083B2 (ja) | セレブロン結合化合物、その組成物及びそれによる治療方法 | |
| JP2024526191A (ja) | セレブロン結合化合物、その組成物及びそれによる治療方法 | |
| HK40061385A (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
| HK40061385B (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
| EA044376B1 (ru) | Соединения замещенного 3-((3-аминофенил)амино)пиперидин-2,6-диона, их композиции и способы лечения с их помощью | |
| JP2024526182A (ja) | セレブロン結合化合物、その組成物及びそれによる治療方法 | |
| JP2024526192A (ja) | セレブロン結合化合物、その組成物及びそれによる治療方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221216 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221228 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20221228 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231214 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240327 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240423 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240522 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7494181 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |